I want to donate

The Haematology research group at the IDIBGI started in 2007 as an extension of the haematology service at ICO Girona. The group is dedicated to clinical and translational studies in relation to diagnostic, prognostic, and therapeutic processes in hemopathies, the group is made up of haematologists, nurses, biologists and technicians.

Main lines of research
  • Study genetic variants involved in the immune response as survival predictors and graft disease against the host after allogenic transplantation of hematopoietic progenitors.
  • Study biological and pharmacogenomic aspects associated with response to the treatment of acute myeloblastic leukaemia
  • Analysis of genetic polymorphisms as predictors of multiple myeloma progression.
  • Study of genetic polymorphisms involved in evolution and the response to treatment of chronic lymphatic leukaemia.
  • Study of cell populations using flow cytometry for the characterization of hemopathies and detection of residual disease.
Strategic objectives
  • To investigate biological, clinical, and epidemiological aspects of haematological diseases
  • To carry out translational research projects focused on finding prognostic factors or treatment response predictors
  • To carry out clinical research, promoting participation in clinical trials for haematological diseases and participating in national or international cooperative groups.

Impact of pre- and/or post-autologous stem cell transplantation exposure to brentuximab vedotin on survival outcomes in patients with high-risk Hodgkin lymphoma

ANNALS OF HEMATOLOGY, 2023, 102, 429-437

Front-line fludarabine-cyclophosphamide-rituximab (FCR) in 110 patients with chronic lymphocytic leukaemia (CLL): real-life experience with long-term outcomes, toxicities and responses to second-line therapies.


Impact of Center-related Characteristics and Macroeconomic Factors on the Outcome of Adult Patients With Acute Lymphoblastic Leukemia Treated With Pediatric-inspired Protocols.

HemaSphere, 2023, 7

Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of Myelofibrosis.

HemaSphere, 2023, 7

Cruz D, Rodríguez-Romanos R, González-Bartulos M, García-Cadenas I, de la Cámara R, Heras I, Buño I, Santos N, Lloveras N, Velarde P, Tuset E, Martínez C, González M, Sanz GF, Ferrá C, Sampol A, Coll R, Pérez-Simón JA, López-Jiménez J, Jurado M, Gallardo D

LAG3 genotype of the donor and clinical outcome after allogeneic transplantation from HLA-identical sibling donors.

Frontiers in Immunology, 2023, 14, 1066393-1066393

Gonzalez-Farre B, Ramis-Zaldivar JE, Castrejón de Anta N, Rivas-Delgado A, Nadeu F, Salmeron-Villalobos J, Enjuanes A, Karube K, Balagué O, Cobo F, Kelleher N, Victoria I, Veloza L, Teixido C, Giné E, Lopez-Guerra M, Quintanilla-Martinez L, Lopez-Guillermo A, Salaverria I, Campo E

Intravascular Large B-Cell Lymphoma Genomic Profile Is Characterized by Alterations in Genes Regulating NF-?B and Immune Checkpoints.


Oñate G, Bataller A, Garrido A, Hoyos M, Arnan M, Vives S, Coll R, Tormo M, Sampol MA, Escoda L, Salamero O, Garcia A, Bargay J, Aljarilla A, Nomdedeu JF, Esteve J, Sierra J, Pratcorona M

Prognostic impact of DNMT3A mutation in acute myeloid leukemia with mutated NPM1

Blood Advances, 2022, 6, 882-890

Bataller A, Garrido A, Guijarro F, Oñate G, Diaz-Beya M, Arnan M, Tormo M, Vives S, Queipo DE Llano MP, Coll R, Gallardo D, Vall-Llovera F, Escoda L, García-Guiñon A, Salamero O, Sampol A, Merchan B, Bargay J, Castaño-Díez S, Esteban D, Oliver-Caldes A, Rivero A, Mozas P, López-Guerra M, Pratcorona M, Zamora L, Costa D, Rozman M, Nomdedeu JF, Colomer D, Brunet S, Sierra J, Esteve J

European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol

Blood Advances, 2022, 6, 1193-1206

Ribera J, Granada I, Morgades M, González T, Ciudad J, Such E, Calasanz MJ, Mercadal S, Coll R, González-Campos J, Tormo M, García-Cadenas I, Gil C, Cervera M, Barba P, Costa D, Ayala R, Bermúdez A, Orfao A, Ribera JM

Prognostic heterogeneity of adult B-cell precursor acute lymphoblastic leukaemia patients with t(1;19)(q23;p13)/ TCF3-PBX1 treated with measurable residual disease-oriented protocols


Dimopoulos MA, Schjesvold F, Doronin V, Vinogradova O, Quach H, Leleu X, Montes YG, Ramasamy K, Pompa A, Levin MD, Lee C, Mellqvist UH, Fenk R, Demarquette H, Sati H, Vorog A, Labotka R, Du J, Darif M, Kumar S

Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial

Competitive projects
Codi oficial: PI20/01353 Start date:01/01/2021 Data fi: 31/12/2023 Investigador/a principal: DAVID GALLARDO GIRALT Organisme finançador: INSTITUTO DE SALUD CARLOS III Ajuda: 135,520 €
Codi oficial: Projecte IJC - Dr. David Gallardo Start date:01/07/2021 Data fi: 30/06/2025 Investigador/a principal: DAVID GALLARDO GIRALT Organisme finançador: FUNDACIÓ INSTITUT DE RECERCA CONTRA LA LEUCÈMIA JOSEP CARRERAS Ajuda: 0 €
Job offers


If you are a researcher and you are interested in collaborating with any of our research groups, please fill in this form.
I am interested in
If you are a student or you want to do an internship with any of our research groups, please fill in this form.
I am interested in